![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00241111 |
Study to determine effectiveness and safety of zoledronic acid and whether it has a pharmaco-economic impact in prostate cancer with bone metastasis.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer With Bone Metastasis |
Drug: zoledronic acid |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Assessment of the Efficacy, Tolerability and Pharmaco-Economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis |
Estimated Enrollment: | 250 |
Study Start Date: | September 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined inclusion / exclusion criteria may apply.
Study ID Numbers: | CZOL446EFR04 |
Study First Received: | October 14, 2005 |
Last Updated: | September 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00241111 |
Health Authority: | France: Institutional Ethical Committee |
Prostate cancer bone metastasis zoledronic acid |
Zoledronic acid Bone Neoplasms Genital Neoplasms, Male Prostatic Diseases Hematologic Diseases Bone neoplasms Urogenital Neoplasms |
Genital Diseases, Male Bone Diseases Diphosphonates Musculoskeletal Diseases Neoplasm Metastasis Bone Marrow Diseases Prostatic Neoplasms |
Neoplasms Neoplastic Processes Neoplasms by Site Pathologic Processes |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |